For Adolescent Patients and Parents/Caregivers of Pediatric Patients The BRAVE Study is evaluating a potential treatment option for Friedreich Ataxia. If your child has been diagnosed with Friedreich Ataxia (FA), they may be eligible for the BRAVE Study. About the BRAVE Study. The BRAVE Study is evaluating how safe a...
Message to the Friedreich Ataxia Community October 7, 2025 Dear Advocacy Partners and FA community members, This morning, we were pleased to share positive interim clinical data for LX2006, our investigational gene therapy, that includes both cardiac and neurological outcome measures. LX2006 (AAVrh10hFXN) is currently being studied in the Lexeo-sponsored...
Patient Information This brochure provides etails about the AROATXN2-1001 Study for individuals with spinocerebellar ataxia type 2 (SCA2)d. It aims to help potential participants decide whether they or someone they know may want to join the study. Eligibility Criteria You may be eligible to participate if you: Are between 18...
Conversation with women and men engaged in our foundation. Today, we present Sébastien HUYNH | LinkedIn. AC: Can you introduce your professional background? SH: My career has allowed me to develop broad skills in management, finance, and accounting. Having grown up in France, I have had the opportunity to work...
Posted on: 2023-10-18– Posted by: Ataxia Canada – Category: publications Deadline: November 18 2023 Dear Members, At the next annual general assembly on December 3rd 2023, we will renew and/or elect members to the Board of Directors. We are seeking to solicit nominations of bilingual candidates that satisfy some of...
The study is being conducted with multiple sites in the United States and Canada seeking to recruit approximately 9 participants aged 18-40 with a diagnosis of FA-associated cardiomyopathy. The study will be conducted by Dr. Antoine Duquette at the CHUM in Montreal. The choice of Montreal as a site reflects...
U.S. Food & Drug Administration Approves Reata Pharmaceuticals’ SKYCLARYS™ (Omaveloxolone) for the Treatment of Adults and Adolescents Aged 16 Years and Older with FA Montreal,QC ., February 28, 2023 – This week marks the approval of the first medication to treat Friedreich’s Ataxia (FA), a milestone for the FA...